Identification
NameAtorvastatin
Accession NumberDB01076  (APRD00055)
TypeSmall Molecule
GroupsApproved
Description

Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.

Structure
Thumb
Synonyms
Lipovastatinklonal
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Atorvastatin CalciumC0GEJ5QCSO 134523-03-8FQCKMBLVYCEXJB-ZUHSGPLBNA-LDetails
Atorvastatin calcium trihydrate48A5M73Z4Q 344423-98-9SHZPNDRIDUBNMH-NIJVSVLQSA-LDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-atorvastatin CalciumTablet20 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-atorvastatin CalciumTablet40 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-atorvastatin CalciumTablet10 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-atorvastatin CalciumTablet80 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Act AtorvastatinTablet80 mgOralActavis Pharma Company2010-05-19Not applicableCanada
Act AtorvastatinTablet40 mgOralActavis Pharma Company2010-05-19Not applicableCanada
Act AtorvastatinTablet10 mgOralActavis Pharma Company2010-05-19Not applicableCanada
Act AtorvastatinTablet20 mgOralActavis Pharma Company2010-05-19Not applicableCanada
AtorvastatinTablet20 mgOralApotex Corporation2013-01-07Not applicableCanada
AtorvastatinTablet10 mgOralPro Doc Limitee2010-05-21Not applicableCanada
AtorvastatinTablet80 mgOralRanbaxy Inc.Not applicableNot applicableCanada
AtorvastatinTablet40 mgOralRatiopharm Inc Division Of Teva Canada Limited2010-05-192013-06-27Canada
AtorvastatinTablet10 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AtorvastatinTablet40 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AtorvastatinTablet80 mgOralPro Doc Limitee2010-05-21Not applicableCanada
AtorvastatinTablet40 mgOralRanbaxy Inc.Not applicableNot applicableCanada
AtorvastatinTablet10 mgOralApotex Corporation2013-01-07Not applicableCanada
AtorvastatinTablet10 mgOralRatiopharm Inc Division Of Teva Canada Limited2010-05-192013-06-27Canada
AtorvastatinTablet40 mgOralSanis Health Inc2010-05-27Not applicableCanada
AtorvastatinTablet40 mgOralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
AtorvastatinTablet10 mgOralRanbaxy Inc.Not applicableNot applicableCanada
AtorvastatinTablet40 mgOralApotex Corporation2013-01-07Not applicableCanada
AtorvastatinTablet20 mgOralPro Doc Limitee2010-05-21Not applicableCanada
AtorvastatinTablet80 mgOralRatiopharm Inc Division Of Teva Canada Limited2010-05-192013-06-27Canada
AtorvastatinTablet20 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AtorvastatinTablet10 mgOralSanis Health Inc2010-05-27Not applicableCanada
AtorvastatinTablet10 mgOralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
AtorvastatinTablet20 mgOralRatiopharm Inc Division Of Teva Canada Limited2010-05-192013-06-27Canada
AtorvastatinTablet80 mgOralSanis Health Inc2010-05-27Not applicableCanada
AtorvastatinTablet80 mgOralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
AtorvastatinTablet80 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AtorvastatinTablet20 mgOralRanbaxy Inc.Not applicableNot applicableCanada
AtorvastatinTablet80 mgOralApotex Corporation2013-01-07Not applicableCanada
AtorvastatinTablet40 mgOralPro Doc Limitee2010-05-21Not applicableCanada
AtorvastatinTablet20 mgOralSanis Health Inc2010-05-27Not applicableCanada
AtorvastatinTablet20 mgOralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
Atorvastatin CalciumTablet, film coated10 mg/1OralRebel Distributors2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralLegacy Pharmaceutical Packaging2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralWatson Pharmaceuticals2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralLegacy Pharmaceutical Packaging2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1Oralbryant ranch prepack2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralLegacy Pharmaceutical Packaging2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralWatson Pharmaceuticals2011-11-30Not applicableUs00591 3777 19 nlmimage10 ba1b5d0a
Atorvastatin CalciumTablet, film coated20 mg/1OralAmerincan Health Packaging2013-07-052016-10-13Us00591 3775 19 nlmimage10 581b2c79
Atorvastatin CalciumTablet, film coated80 mg/1Oralbryant ranch prepack2013-01-28Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1Oralbryant ranch prepack2013-01-28Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralLegacy Pharmaceutical Packaging2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralLegacy Pharmaceutical Packaging2011-11-30Not applicableUs59762 0156 01 nlmimage10 093a84a4
Atorvastatin CalciumTablet, film coated40 mg/1OralRebel Distributors1996-12-17Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralWatson Pharmaceuticals2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralLegacy Pharmaceutical Packaging2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralAmerincan Health Packaging2013-07-052016-10-13Us
Atorvastatin CalciumTablet, film coated40 mg/1OralLegacy Pharmaceutical Packaging2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralLegacy Pharmaceutical Packaging2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralRebel Distributors1996-12-17Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralWatson Pharmaceuticals2011-11-30Not applicableUs00591 3776 19 nlmimage10 511b28b9
Atorvastatin CalciumTablet, film coated10 mg/1OralAmerincan Health Packaging2013-07-052016-10-13Us00591 3774 19 nlmimage10 491b24f9
Atorvastatin CalciumTablet, film coated10 mg/1OralLegacy Pharmaceutical Packaging2011-11-30Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralLegacy Pharmaceutical Packaging2013-01-01Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralRebel Distributors1996-12-17Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1Oralbryant ranch prepack2013-01-28Not applicableUs
Atorvastatin-10Tablet10 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Atorvastatin-10Tablet10 mgOralPro Doc Limitee2010-06-012011-07-27Canada
Atorvastatin-20Tablet20 mgOralPro Doc Limitee2010-06-012011-07-27Canada
Atorvastatin-20Tablet20 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Atorvastatin-40Tablet40 mgOralPro Doc Limitee2010-06-012011-07-27Canada
Atorvastatin-40Tablet40 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Atorvastatin-80Tablet80 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Atorvastatin-80Tablet80 mgOralPro Doc Limitee2010-06-012011-07-27Canada
Auro-atorvastatinTablet40 mgOralAuro Pharma Inc2013-06-13Not applicableCanada
Auro-atorvastatinTablet20 mgOralAuro Pharma Inc2013-06-13Not applicableCanada
Auro-atorvastatinTablet80 mgOralAuro Pharma Inc2013-06-13Not applicableCanada
Auro-atorvastatinTablet10 mgOralAuro Pharma Inc2013-06-13Not applicableCanada
Ava-atorvastatinTablet20 mgOralAvanstra Inc2011-11-282014-08-21Canada
Ava-atorvastatinTablet40 mgOralAvanstra Inc2011-11-282014-08-21Canada
Ava-atorvastatinTablet10 mgOralAvanstra Inc2011-11-282014-08-21Canada
Ava-atorvastatinTablet80 mgOralAvanstra Inc2011-11-282014-08-21Canada
Dom-atorvastatinTablet20 mgOralDominion Pharmacal2013-08-09Not applicableCanada
Dom-atorvastatinTablet10 mgOralDominion Pharmacal2010-12-17Not applicableCanada
Dom-atorvastatinTablet40 mgOralDominion Pharmacal2013-08-09Not applicableCanada
Dom-atorvastatinTablet20 mgOralDominion Pharmacal2010-12-17Not applicableCanada
Dom-atorvastatinTablet10 mgOralDominion Pharmacal2013-08-09Not applicableCanada
Dom-atorvastatinTablet80 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-atorvastatinTablet80 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-atorvastatinTablet40 mgOralDominion Pharmacal2010-12-17Not applicableCanada
Gd-atorvastatinTablet20 mgOralGenmed A Division Of Pfizer Canada Inc2010-05-202017-03-10Canada
Gd-atorvastatinTablet40 mgOralGenmed A Division Of Pfizer Canada Inc2010-05-202017-03-10Canada
Gd-atorvastatinTablet10 mgOralGenmed A Division Of Pfizer Canada Inc2010-05-202017-03-10Canada
Gd-atorvastatinTablet80 mgOralGenmed A Division Of Pfizer Canada Inc2010-05-202017-03-10Canada
Jamp-atorvastatinTablet10 mgOralJamp Pharma Corporation2012-09-10Not applicableCanada
Jamp-atorvastatinTablet80 mgOralJamp Pharma Corporation2012-09-10Not applicableCanada
Jamp-atorvastatinTablet20 mgOralJamp Pharma Corporation2012-09-10Not applicableCanada
Jamp-atorvastatinTablet40 mgOralJamp Pharma Corporation2012-09-10Not applicableCanada
LipitorTablet, film coated20 mg/1OralA S Medication Solutions1997-03-112017-06-20Us
LipitorTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2004-03-12Not applicableUs
LipitorTablet, film coated80 mg/1OralAphena Pharma Solutions Tennessee, Inc.2000-04-07Not applicableUs
LipitorTablet80 mgOralPfizer2001-06-29Not applicableCanada
LipitorTablet, film coated20 mg/1Oralbryant ranch prepack1996-12-17Not applicableUs
LipitorTablet, film coated20 mg/1Oralbryant ranch prepack1996-12-17Not applicableUs
LipitorTablet, film coated80 mg/1OralPHARMAKON, LLC2010-12-01Not applicableUs
LipitorTablet40 mgOralPfizer1997-03-05Not applicableCanada
LipitorTablet, film coated10 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-05Not applicableUs
LipitorTablet, film coated40 mg/1OralPHARMAKON, LLC2010-12-01Not applicableUs
LipitorTablet, film coated10 mg/1OralPhysicians Total Care, Inc.1997-05-05Not applicableUs
LipitorTablet, film coated10 mg/1OralCardinal Health1996-12-17Not applicableUs
LipitorTablet, film coated40 mg/1Oralbryant ranch prepack1996-12-17Not applicableUs
LipitorTablet, film coated80 mg/1OralCardinal Health2000-04-07Not applicableUs00071 0158 23 nlmimage10 0a088504
LipitorTablet, film coated80 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-05Not applicableUs
LipitorTablet, film coated10 mg/1OralPHARMAKON, LLC2010-12-01Not applicableUs
LipitorTablet, film coated40 mg/1OralA S Medication Solutions1998-06-082017-06-20Us
LipitorTablet, film coated40 mg/1OralPhysicians Total Care, Inc.2000-07-06Not applicableUs
LipitorTablet, film coated40 mg/1OralAphena Pharma Solutions Tennessee, Inc.1996-12-17Not applicableUs
LipitorTablet, film coated40 mg/1Oralbryant ranch prepack1996-12-17Not applicableUs00071 0157 23 nlmimage10 4e1b2769
LipitorTablet10 mgOralPfizer1997-03-05Not applicableCanada
LipitorTablet, film coated10 mg/1OralRemedy Repack2013-06-042016-04-05Us
LipitorTablet, film coated40 mg/1OralRebel Distributors1996-12-17Not applicableUs
LipitorTablet, film coated20 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-05Not applicableUs
LipitorTablet, film coated20 mg/1OralCardinal Health1996-12-17Not applicableUs00071 0156 23 nlmimage10 741c3a41
LipitorTablet, film coated10 mg/1OralA S Medication Solutions1997-03-112017-06-20Us
LipitorTablet, film coated40 mg/1Oralbryant ranch prepack1996-12-17Not applicableUs
LipitorTablet, film coated10 mg/1Oralbryant ranch prepack1996-12-17Not applicableUs
LipitorTablet20 mgOralPfizer1997-03-05Not applicableCanada
LipitorTablet, film coated20 mg/1OralRemedy Repack2013-05-142016-03-16Us
LipitorTablet, film coated20 mg/1OralPHARMAKON, LLC2010-12-01Not applicableUs
LipitorTablet, film coated80 mg/1OralA S Medication Solutions2002-04-082017-06-20Us
LipitorTablet, film coated80 mg/1OralPhysicians Total Care, Inc.2006-01-11Not applicableUs
LipitorTablet, film coated80 mg/1Oralbryant ranch prepack2000-04-07Not applicableUs
LipitorTablet, film coated40 mg/1OralCardinal Health1996-12-17Not applicableUs
LipitorTablet, film coated40 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-05Not applicableUs
Mar-atorvastatinTablet10 mgOralMarcan Pharmaceuticals Inc2017-05-12Not applicableCanada
Mar-atorvastatinTablet20 mgOralMarcan Pharmaceuticals Inc2017-05-12Not applicableCanada
Mar-atorvastatinTablet40 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-atorvastatinTablet80 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-atorvastatinTablet20 mgOralMylan Pharmaceuticals2014-06-03Not applicableCanada
Mylan-atorvastatinTablet10 mgOralMylan Pharmaceuticals2011-10-172016-05-20Canada
Mylan-atorvastatinTablet80 mgOralMylan Pharmaceuticals2011-10-172016-05-20Canada
Mylan-atorvastatinTablet40 mgOralMylan Pharmaceuticals2014-06-03Not applicableCanada
Mylan-atorvastatinTablet20 mgOralMylan Pharmaceuticals2011-10-172016-05-20Canada
Mylan-atorvastatinTablet10 mgOralMylan Pharmaceuticals2014-06-03Not applicableCanada
Mylan-atorvastatinTablet80 mgOralMylan Pharmaceuticals2014-06-03Not applicableCanada
Mylan-atorvastatinTablet40 mgOralMylan Pharmaceuticals2011-10-172016-05-20Canada
Novo-atorvastatinTablet20 mgOralNovopharm Limited2010-05-192015-10-26Canada
Novo-atorvastatinTablet10 mgOralNovopharm Limited2010-05-192015-10-26Canada
Novo-atorvastatinTablet40 mgOralNovopharm Limited2010-05-192015-10-26Canada
Novo-atorvastatinTablet80 mgOralNovopharm Limited2010-05-192015-10-26Canada
Ntp-atorvastatinTablet20 mgOralTevaNot applicableNot applicableCanada
Ntp-atorvastatinTablet40 mgOralTevaNot applicableNot applicableCanada
Ntp-atorvastatinTablet10 mgOralTevaNot applicableNot applicableCanada
Ntp-atorvastatinTablet80 mgOralTevaNot applicableNot applicableCanada
PMS-atorvastatinTablet40 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-atorvastatinTablet10 mgOralPharmascience Inc2013-03-26Not applicableCanada
PMS-atorvastatinTablet80 mgOralPharmascience Inc2013-03-26Not applicableCanada
PMS-atorvastatinTablet10 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-atorvastatinTablet40 mgOralPharmascience Inc2010-05-19Not applicableCanada
PMS-atorvastatinTablet80 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-atorvastatinTablet10 mgOralPharmascience Inc2010-05-19Not applicableCanada
PMS-atorvastatinTablet20 mgOralPharmascience Inc2013-03-26Not applicableCanada
PMS-atorvastatinTablet20 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-atorvastatinTablet80 mgOralPharmascience Inc2010-05-19Not applicableCanada
PMS-atorvastatinTablet40 mgOralPharmascience Inc2013-03-26Not applicableCanada
PMS-atorvastatinTablet20 mgOralPharmascience Inc2010-05-19Not applicableCanada
Q-gen AtorvastatinTablet20 mgOralQ Gen Pharmaceuticals IncNot applicableNot applicableCanada
Q-gen AtorvastatinTablet10 mgOralQ Gen Pharmaceuticals IncNot applicableNot applicableCanada
Q-gen AtorvastatinTablet40 mgOralQ Gen Pharmaceuticals IncNot applicableNot applicableCanada
Q-gen AtorvastatinTablet80 mgOralQ Gen Pharmaceuticals IncNot applicableNot applicableCanada
Ran-atorvastatinTablet10 mgOralRanbaxy Inc.2010-05-20Not applicableCanada
Ran-atorvastatinTablet80 mgOralRanbaxy Inc.2010-05-20Not applicableCanada
Ran-atorvastatinTablet20 mgOralRanbaxy Inc.2010-05-20Not applicableCanada
Ran-atorvastatinTablet40 mgOralRanbaxy Inc.2010-05-20Not applicableCanada
Ratio-atorvastatinTablet10 mgOralTeva2010-05-19Not applicableCanada
Ratio-atorvastatinTablet80 mgOralTeva2010-05-19Not applicableCanada
Ratio-atorvastatinTablet20 mgOralTeva2010-05-19Not applicableCanada
Ratio-atorvastatinTablet40 mgOralTeva2010-05-19Not applicableCanada
Rbx-atorvastatinTablet10 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Rbx-atorvastatinTablet80 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Rbx-atorvastatinTablet20 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Rbx-atorvastatinTablet40 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Reddy-atorvastatinTablet40 mgOralDr Reddy's Laboratories2015-06-22Not applicableCanada
Reddy-atorvastatinTablet10 mgOralDr Reddy's Laboratories2015-06-22Not applicableCanada
Reddy-atorvastatinTablet80 mgOralDr Reddy's Laboratories2015-06-22Not applicableCanada
Reddy-atorvastatinTablet20 mgOralDr Reddy's Laboratories2015-06-22Not applicableCanada
Riva-atorvastatinTablet20 mgOralLaboratoire Riva Inc2014-03-20Not applicableCanada
Riva-atorvastatinTablet40 mgOralLaboratoire Riva Inc2014-03-20Not applicableCanada
Riva-atorvastatinTablet10 mgOralLaboratoire Riva Inc2014-03-20Not applicableCanada
Riva-atorvastatinTablet80 mgOralLaboratoire Riva Inc2014-03-20Not applicableCanada
Sandoz AtorvastatinTablet10 mgOralSandoz Canada Incorporated2010-05-19Not applicableCanada
Sandoz AtorvastatinTablet80 mgOralSandoz Canada Incorporated2010-05-19Not applicableCanada
Sandoz AtorvastatinTablet20 mgOralSandoz Canada Incorporated2010-05-19Not applicableCanada
Sandoz AtorvastatinTablet40 mgOralSandoz Canada Incorporated2010-05-19Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-atorvastatinTablet80 mgOralApotex Corporation2010-05-19Not applicableCanada
Apo-atorvastatinTablet40 mgOralApotex Corporation2010-05-19Not applicableCanada
Apo-atorvastatinTablet10 mgOralApotex Corporation2010-05-19Not applicableCanada
Apo-atorvastatinTablet20 mgOralApotex Corporation2010-05-19Not applicableCanada
Atorvastatin CalciumTablet, film coated40 mg/1OralNorthwind Pharmaceuticals2014-10-08Not applicableUs
Atorvastatin CalciumTablet20 mg/1OralDirectrx2015-01-01Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1Oralbryant ranch prepack2011-12-01Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralClinical Solutions Wholsesale2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralAphena Pharma Solutions Tennessee, Inc.2013-07-08Not applicableUs
Atorvastatin CalciumTablet20 mg/1OralRemedy Repack2016-07-122017-02-14Us
Atorvastatin CalciumTablet, film coated40 mg/1OralA S Medication Solutions2012-05-292017-06-20Us
Atorvastatin CalciumTablet, film coated20 mg/1OralAphena Pharma Solutions Tennessee, Inc.2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralApotex Corporation2012-05-29Not applicableUs
Atorvastatin CalciumTablet40 mg/1OralRemedy Repack2017-04-03Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralDispensing Solutions, Inc.2011-12-01Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralCarilion Materials Management2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralAkron Pharma Inc2017-05-19Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralAv Pak2016-06-24Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralUnit Dose Services2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralAv Kare, Inc.2013-07-08Not applicableUs
Atorvastatin CalciumTablet20 mg/1OralDr Reddy's Laboratories2012-07-17Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralRemedy Repack2013-10-072016-10-13Us
Atorvastatin CalciumTablet, film coated10 mg/1OralGolden State Medical Supply2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralKremers Urban2013-04-05Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralAmerincan Health Packaging2013-07-09Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralPreferreed Pharmaceuticals Inc.2016-02-16Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralUnit Dose Services2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralCardinal Health2013-07-09Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralNucare Pharmaceuticals, Inc.2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralApotex Corporation2012-05-29Not applicableUs60505 2671 09 nlmimage10 ab1dd5ae
Atorvastatin CalciumTablet, film coated10 mg/1OralTeva2017-04-26Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralAphena Pharma Solutions Tennessee, Inc.2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralUnit Dose Services2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralCambridge Therapeutics Technologies, Llc2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralAphena Pharma Solutions Tennessee, Inc.2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralCardinal Health2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralA S Medication Solutions2012-05-292017-06-20Us
Atorvastatin CalciumTablet, film coated80 mg/1OralAv Kare, Inc.2013-07-08Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2013-07-09Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2011-12-02Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralGolden State Medical Supply2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralKremers Urban2013-04-05Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralAmerincan Health Packaging2013-07-09Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralAkron Pharma Inc2017-05-19Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralClinical Solutions Wholsesale2012-05-29Not applicableUs
Atorvastatin CalciumTablet10 mg/1OralRemedy Repack2013-05-152016-04-05Us
Atorvastatin CalciumTablet, film coated20 mg/1Oralbryant ranch prepack2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralDispensing Solutions, Inc.2011-12-01Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralSt. Marys Medical Park Pharmacy2014-04-20Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralMajor2014-10-31Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralA S Medication Solutions2013-04-052017-06-20Us
Atorvastatin CalciumTablet, film coated10 mg/1OralRemedy Repack2016-09-192017-02-10Us
Atorvastatin CalciumTablet, film coated10 mg/1OralCambridge Therapeutics Technologies, Llc2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralDispensing Solutions, Inc.2011-12-01Not applicableUs63304 0830 90 nlmimage10 e91c7493
Atorvastatin CalciumTablet, film coated80 mg/1OralLiberty Pharmaceuticals, Inc.2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralAidarex Pharmaceuticals LLC2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralAv Pak2016-06-24Not applicableUs
Atorvastatin CalciumTablet40 mg/1OralUnit Dose Services2012-07-17Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralLegacy Pharmaceutical Packaging2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralCardinal Health2013-07-09Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralAidarex Pharmaceuticals LLC2013-04-05Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralProficient Rx LP2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralTeva2017-04-26Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralPreferreed Pharmaceuticals Inc.2013-04-15Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/301OralNorthwind Pharmaceuticals2014-04-25Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralPhysicians Total Care, Inc.2011-12-02Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralGolden State Medical Supply2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralKremers Urban2013-04-05Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralAmerincan Health Packaging2013-07-09Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralRemedy Repack2013-07-05Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralRemedy Repack2013-07-312017-02-14Us
Atorvastatin CalciumTablet, film coated80 mg/301OralNorthwind Pharmaceuticals2014-04-28Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralDirectrx2015-01-01Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1Oralbryant ranch prepack2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralSt. Marys Medical Park Pharmacy2014-04-20Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralMajor2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralA S Medication Solutions2013-04-052017-06-20Us
Atorvastatin CalciumTablet, film coated10 mg/1OralRemedy Repack2016-09-012017-02-10Us
Atorvastatin CalciumTablet, film coated80 mg/1OralA S Medication Solutions2012-05-292017-06-20Us
Atorvastatin CalciumTablet, film coated10 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralRemedy Repack2017-01-31Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralApotex Corporation2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralInternational Laboratories, Llc2014-06-01Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralLegacy Pharmaceutical Packaging2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralAidarex Pharmaceuticals LLC2016-08-04Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralAv Pak2016-06-24Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralUnit Dose Services2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralAv Kare, Inc.2013-07-08Not applicableUs
Atorvastatin CalciumTablet40 mg/1OralDr Reddy's Laboratories2012-07-17Not applicableUs
Atorvastatin CalciumTablet40 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Atorvastatin CalciumTablet80 mg/1OralRemedy Repack2016-09-26Not applicableUs
Atorvastatin CalciumTablet10 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2012-07-17Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralCardinal Health2013-07-09Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralRemedy Repack2017-02-15Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralSt. Marys Medical Park Pharmacy2014-01-15Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralTeva2017-04-26Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralPreferreed Pharmaceuticals Inc.2013-04-15Not applicableUs60505 2578 09 nlmimage10 a93854c2
Atorvastatin CalciumTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2011-12-01Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2011-12-02Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralDispensing Solutions, Inc.2011-12-01Not applicableUs
Atorvastatin CalciumTablet20 mg/1OralRemedy Repack2015-05-112017-04-14Us
Atorvastatin CalciumTablet, film coated80 mg/1OralMajor2014-10-31Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralA S Medication Solutions2013-04-052017-06-20Us
Atorvastatin CalciumTablet80 mg/1OralDr Reddy's Laboratories2012-07-17Not applicableUs55111 0124 05 nlmimage10 8a3a4572
Atorvastatin CalciumTablet, film coated10 mg/1OralDispensing Solutions, Inc.2011-12-01Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralPd Rx Pharmaceuticals, Inc.2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralAv Pak2016-06-24Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralUnit Dose Services2012-05-29Not applicableUs
Atorvastatin CalciumTablet10 mg/1OralDr Reddy's Laboratories2012-07-17Not applicableUs55111 0121 05 nlmimage10 3f3a9fa4
Atorvastatin CalciumTablet, film coated40 mg/1OralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralUnit Dose Services2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralProficient Rx LP2012-05-29Not applicableUs
Atorvastatin CalciumTablet40 mg/1OralRed Pharm Drug, Inc.2012-07-17Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralUnit Dose Services2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralNorthwind Pharmaceuticals2014-04-03Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralAphena Pharma Solutions Tennessee, Inc.2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralRemedy Repack2013-01-282018-01-04Us
Atorvastatin CalciumTablet, film coated80 mg/1OralUnit Dose Services2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralAv Kare, Inc.2013-07-08Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2013-07-09Not applicableUs60505 2579 09 nlmimage10 a538d296
Atorvastatin CalciumTablet20 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs55111 0122 05 nlmimage10 c53de2cf
Atorvastatin CalciumTablet, film coated40 mg/1OralGolden State Medical Supply2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralKremers Urban2013-04-05Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralAmerincan Health Packaging2013-07-09Not applicableUs60505 2580 09 nlmimage10 9b1dcdfe
Atorvastatin CalciumTablet, film coated10 mg/1OralAkron Pharma Inc2017-05-19Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralCardinal Health2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/301OralNorthwind Pharmaceuticals2014-03-11Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1Oralbryant ranch prepack2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralMed Vantx, Inc.2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralSt. Marys Medical Park Pharmacy2014-04-20Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralMajor2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralA S Medication Solutions2013-04-052017-06-20Us
Atorvastatin CalciumTablet, film coated80 mg/1OralRemedy Repack2016-09-12Not applicableUs
Atorvastatin CalciumTablet, film coated20 mg/1OralCambridge Therapeutics Technologies, Llc2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralCambridge Therapeutics Technologies, Llc2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralApotex Corporation2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralCambridge Therapeutics Technologies, Llc2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralProficient Rx LP2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralRemedy Repack2013-01-16Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralDispensing Solutions, Inc.2011-12-01Not applicableUs
Atorvastatin CalciumTablet40 mg/1OralRemedy Repack2015-06-022017-04-14Us55111 0123 05 nlmimage10 ca3de53f
Atorvastatin CalciumTablet, film coated40 mg/1OralBlenheim Pharmacal, Inc.2015-04-20Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralA S Medication Solutions2013-09-192017-06-20Us
Atorvastatin CalciumTablet, film coated10 mg/1OralLegacy Pharmaceutical Packaging2012-05-29Not applicableUs
Atorvastatin CalciumTablet, film coated10 mg/1OralCardinal Health2013-07-09Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralCardinal Health2014-10-31Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralDirectrx2015-01-01Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralTeva2017-04-26Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralPreferreed Pharmaceuticals Inc.2013-04-15Not applicableUs
Atorvastatin CalciumTablet, film coated80 mg/1OralPd Rx Pharmaceuticals, Inc.2013-04-05Not applicableUs
Atorvastatin CalciumTablet, film coated40 mg/1OralPhysicians Total Care, Inc.2011-12-01Not applicableUs
LipitorTablet10 mg/1OralDirectrx2016-01-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AtogalIngers (Czech Republic)
CardylPfizer (Spain)
FaboximFabop (Argentina)
HipolixanPasteur (Chile)
LipotropicDrugtech (Chile)
LiprimarPfizer (Hungary, Ukraine), Goedecke (Russia)
LowdenSaval (Chile)
NormalipQuesada (Argentina)
SincolIndeco (Argentina)
SortisPfizer (Austria, Czech Republic, Germany, Hungary, Poland, Portugal, Switzerland), Godecke (Germany), Parke, Davis (Germany)
TorvacardZentiva (Czech Republic, Hungary, Poland, Russia, Ukraine)
TorvastPfizer (Italy)
TotalipGuidotti (Italy)
TulipLek (Czech Republic, Russia), Wermar (Mexico), Sandoz (Poland, Ukraine), Pharmacia (Spain)
VastinaPenn (Argentina)
XanatorSieger (Greece)
XaratorParke, Davis (Italy)
ZurinelPrater (Chile)
Brand mixtures
NameLabellerIngredients
Amlodipine Besylate and Atorvastatin CalciumDr Reddy's Laboratories
Apo-amlodipine-atorvastatinApotex Corporation
CaduetPhysicians Total Care, Inc.
Gd-amlodipine/atorvastatinGenmed A Division Of Pfizer Canada Inc
LiptruzetMerck Sharp & Dohme Limited
Mylan-amlodipine/atorvastatinMylan Pharmaceuticals
Pendo-amlodipine-atorvastatinPendopharm Division Of De Pharmascience Inc
PMS-amlodipine-atorvastatinPharmascience Inc
Categories
UNIIA0JWA85V8F
CAS number134523-00-5
WeightAverage: 558.6398
Monoisotopic: 558.253000445
Chemical FormulaC33H35FN2O5
InChI KeyXUKUURHRXDUEBC-KAYWLYCHSA-N
InChI
InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
IUPAC Name
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
SMILES
CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Pharmacology
Indication

May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels.

Structured Indications
Pharmacodynamics

Atorvastatin, a selective, competitive HMG-CoA reductase inhibitor, is used to lower serum total and LDL cholesterol, apoB, and triglyceride levels while increasing HDL cholesterol. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality. Atorvastatin has a unique structure, long half-life, and hepatic selectivity, explaining its greater LDL-lowering potency compared to other HMG-CoA reductase inhibitors.

Mechanism of action

Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.

TargetKindPharmacological actionActionsOrganismUniProt ID
3-hydroxy-3-methylglutaryl-coenzyme A reductaseProteinyes
inhibitor
HumanP04035 details
Dipeptidyl peptidase 4Proteinno
inhibitor
HumanP27487 details
Aryl hydrocarbon receptorProteinunknown
agonist
HumanP35869 details
Related Articles
Absorption

Atorvastatin is rapidly absorbed after oral administration with maximum plasma concentrations achieved in 1 to 2 hours. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic bioavailability is due to presystemic clearance by gastrointestinal mucosa and first-pass metabolism in the liver.

Volume of distribution

381 L

Protein binding

>98% bound to plasma proteins

Metabolism

Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. CYP3A4 is also involved in the metabolism of atorvastatin.

SubstrateEnzymesProduct
Atorvastatin
para-hydroxyatorvastatinDetails
Atorvastatin
ortho-hydroxyatorvastatinDetails
para-hydroxyatorvastatin
Not Available
para-hydroxyatorvastatin lactoneDetails
ortho-hydroxyatorvastatin
Not Available
ortho-hydroxyatorvastatin lactoneDetails
Atorvastatin
Not Available
Atorvastatin lactoneDetails
Route of elimination

Eliminated primarily in bile after hepatic and/or extrahepatic metabolism. Does not appear to undergo significant enterohepatic recirculation. Less than 2% of the orally administered dose is recovered in urine.

Half life

14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites

ClearanceNot Available
Toxicity

Generally well-tolerated. Side effects may include myalgia, constipation, asthenia, abdominal pain, and nausea. Other possible side effects include myotoxicity (myopathy, myositis, rhabdomyolysis) and hepatotoxicity. To avoid toxicity in Asian patients, lower doses should be considered.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Kinesin-like protein KIF6---(C;C) / (C;T)C Allele Effect Directly StudiedImproved response to statin drugs Details
3-hydroxy-3-methylglutaryl-coenzyme A reductase---(A;T)T Allele Effect Directly StudiedReduced response to statin drugs Details
Multidrug resistance protein 1MDR1*T(T;T) / (C;T)T Allele (C3435T) Effect Directly StudiedLarger reduction in LDL and smaller increase in HDL cholesterol in females Details
Cytochrome P450 3A4CYP3A4*1B(G;G) / (A;G)A > G Effect Directly StudiedBetter response Details
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Atorvastatin can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Atorvastatin can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Atorvastatin can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
AbirateroneThe serum concentration of Atorvastatin can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Atorvastatin.Approved
AcenocoumarolAtorvastatin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Atorvastatin.Approved
AcetohexamideAtorvastatin may increase the hypoglycemic activities of Acetohexamide.Withdrawn
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Atorvastatin.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Atorvastatin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Atorvastatin.Experimental
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Atorvastatin.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Atorvastatin.Approved, Investigational
AlogliptinThe serum concentration of Atorvastatin can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Atorvastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
Aluminum hydroxideThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Atorvastatin.Approved, Investigational
AmiodaroneThe metabolism of Atorvastatin can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Atorvastatin.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Atorvastatin.Approved
AmprenavirThe serum concentration of Atorvastatin can be increased when it is combined with Amprenavir.Approved
Antithrombin III humanThe serum concentration of Atorvastatin can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Atorvastatin can be increased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Atorvastatin can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Atorvastatin can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Atorvastatin can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Atorvastatin.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Atorvastatin.Approved, Investigational
AtazanavirThe serum concentration of Atorvastatin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Atorvastatin.Approved
AtomoxetineThe metabolism of Atorvastatin can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Atorvastatin.Approved, Investigational
AzithromycinAzithromycin may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
BatimastatThe serum concentration of Atorvastatin can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Atorvastatin can be increased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Atorvastatin can be increased when it is combined with Benzamidine.Experimental
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Atorvastatin.Approved, Vet Approved
BexaroteneThe serum concentration of Atorvastatin can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
Bismuth SubcitrateThe serum concentration of Atorvastatin can be decreased when it is combined with Bismuth Subcitrate.Approved
BivalirudinThe serum concentration of Atorvastatin can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Atorvastatin can be increased when it is combined with Boceprevir.Approved, Investigational
BortezomibThe metabolism of Atorvastatin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Atorvastatin can be increased when combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Atorvastatin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atorvastatin.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Atorvastatin.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Atorvastatin.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Atorvastatin.Approved
Calcium carbonateThe serum concentration of Atorvastatin can be decreased when it is combined with Calcium carbonate.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Atorvastatin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Atorvastatin.Approved
CandoxatrilThe serum concentration of Atorvastatin can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Atorvastatin can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Atorvastatin can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Atorvastatin can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Atorvastatin.Approved
CelecoxibThe metabolism of Atorvastatin can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Atorvastatin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Atorvastatin.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Atorvastatin.Approved, Vet Approved
ChlorpropamideAtorvastatin may increase the hypoglycemic activities of Chlorpropamide.Approved
CholestyramineThe serum concentration of Atorvastatin can be decreased when it is combined with Cholestyramine.Approved
ChymostatinThe serum concentration of Atorvastatin can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Atorvastatin can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Atorvastatin can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Atorvastatin.Approved
CimetidineThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Atorvastatin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Atorvastatin.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Atorvastatin.Approved
ClarithromycinThe serum concentration of Atorvastatin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Atorvastatin can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Atorvastatin.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Atorvastatin.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Atorvastatin.Approved
ClopidogrelThe metabolism of Atorvastatin can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Atorvastatin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Atorvastatin.Approved
CobicistatThe serum concentration of Atorvastatin can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Atorvastatin.Approved
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
ColesevelamThe serum concentration of Atorvastatin can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Atorvastatin can be decreased when it is combined with Colestipol.Approved
ConivaptanThe serum concentration of Atorvastatin can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Atorvastatin.Approved
CrizotinibThe metabolism of Atorvastatin can be decreased when combined with Crizotinib.Approved
CyclosporineThe serum concentration of Atorvastatin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Atorvastatin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Atorvastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Atorvastatin.Approved
DabrafenibThe serum concentration of Atorvastatin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Atorvastatin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Atorvastatin.Approved
DanazolThe serum concentration of Atorvastatin can be increased when it is combined with Danazol.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Atorvastatin.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Daptomycin.Approved, Investigational
DarunavirThe serum concentration of Atorvastatin can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Atorvastatin can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Atorvastatin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Atorvastatin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Atorvastatin.Approved
DeferasiroxThe serum concentration of Atorvastatin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Atorvastatin can be decreased when combined with Delavirdine.Approved
DexamethasoneThe serum concentration of Atorvastatin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Atorvastatin.Approved, Illicit, Vet Approved
DicoumarolAtorvastatin may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Atorvastatin.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Atorvastatin.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Atorvastatin.Approved
DihydroergotamineThe metabolism of Atorvastatin can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Atorvastatin.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Atorvastatin.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Atorvastatin.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Atorvastatin.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Atorvastatin.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Atorvastatin.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Atorvastatin.Approved, Investigational
DoxycyclineThe metabolism of Atorvastatin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Atorvastatin can be increased when it is combined with Dronedarone.Approved
EcabetThe serum concentration of Atorvastatin can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Atorvastatin.Approved
EfavirenzThe serum concentration of Atorvastatin can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Atorvastatin can be increased when it is combined with Elafin.Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Atorvastatin.Approved, Investigational
EltrombopagThe serum concentration of Atorvastatin can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Atorvastatin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Atorvastatin can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Atorvastatin can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Atorvastatin can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Atorvastatin.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Atorvastatin.Approved, Investigational
ErythromycinThe metabolism of Atorvastatin can be decreased when combined with Erythromycin.Approved, Vet Approved
ErythromycinThe serum concentration of Atorvastatin can be increased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Atorvastatin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Atorvastatin.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Atorvastatin.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Atorvastatin.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Atorvastatin.Approved
Ethyl biscoumacetateAtorvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Atorvastatin.Approved
EtravirineThe serum concentration of Atorvastatin can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Atorvastatin.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Atorvastatin.Approved
FelodipineThe metabolism of Atorvastatin can be decreased when combined with Felodipine.Approved, Investigational
FenofibrateThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Atorvastatin.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atorvastatin.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Atorvastatin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Atorvastatin.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Atorvastatin.Approved
FluconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Fluconazole.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Atorvastatin.Approved
FluvoxamineThe metabolism of Atorvastatin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Atorvastatin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Atorvastatin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Atorvastatin can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Atorvastatin can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Atorvastatin can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Atorvastatin can be increased when it is combined with Gabexate.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Atorvastatin.Approved, Investigational
GeldanamycinThe serum concentration of Atorvastatin can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Atorvastatin.Approved
GemfibrozilGemfibrozil may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
GlibornurideAtorvastatin may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideAtorvastatin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAtorvastatin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAtorvastatin may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneAtorvastatin may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideAtorvastatin may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideAtorvastatin may increase the hypoglycemic activities of Glyburide.Approved
GM6001The serum concentration of Atorvastatin can be increased when it is combined with GM6001.Experimental
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Atorvastatin.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Atorvastatin.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Atorvastatin.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Atorvastatin.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Atorvastatin.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Atorvastatin.Approved
IdelalisibThe serum concentration of Atorvastatin can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Atorvastatin can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Atorvastatin.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Atorvastatin.Approved
IndinavirThe serum concentration of Atorvastatin can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Atorvastatin.Approved, Investigational
Insulin PorkAtorvastatin may increase the hypoglycemic activities of Insulin Pork.Approved
IrbesartanThe metabolism of Atorvastatin can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Atorvastatin.Approved, Investigational
IsavuconazoniumThe metabolism of Atorvastatin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe serum concentration of Atorvastatin can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsradipineThe metabolism of Atorvastatin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Atorvastatin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Atorvastatin.Approved, Vet Approved
IxazomibThe serum concentration of Atorvastatin can be increased when it is combined with Ixazomib.Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Atorvastatin.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Atorvastatin can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Atorvastatin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Atorvastatin.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Atorvastatin.Approved, Investigational
Lanthanum carbonateThe serum concentration of Lanthanum carbonate can be decreased when it is combined with Atorvastatin.Approved
LapatinibThe metabolism of Atorvastatin can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Atorvastatin.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Atorvastatin.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Atorvastatin.Approved
LepirudinThe serum concentration of Atorvastatin can be increased when it is combined with Lepirudin.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Atorvastatin.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Atorvastatin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Atorvastatin.Approved
LinagliptinThe serum concentration of Atorvastatin can be increased when it is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Atorvastatin can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Atorvastatin.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Atorvastatin.Approved
LopinavirThe serum concentration of Atorvastatin can be increased when it is combined with Lopinavir.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Atorvastatin.Approved
LovastatinThe metabolism of Atorvastatin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Atorvastatin can be increased when it is combined with Lumacaftor.Approved
MagaldrateThe serum concentration of Atorvastatin can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium HydroxideThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium TrisilicateThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Atorvastatin.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Atorvastatin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Atorvastatin.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Atorvastatin.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Atorvastatin.Approved, Illicit
MifepristoneThe serum concentration of Atorvastatin can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Atorvastatin.Approved
MitotaneThe serum concentration of Atorvastatin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Atorvastatin.Approved, Investigational
ModafinilThe serum concentration of Atorvastatin can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Atorvastatin can be increased when it is combined with Moexipril.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Atorvastatin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Atorvastatin.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Atorvastatin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololThe serum concentration of Nadolol can be increased when it is combined with Atorvastatin.Approved
NafamostatThe serum concentration of Atorvastatin can be increased when it is combined with Nafamostat.Approved, Investigational
NafcillinThe serum concentration of Atorvastatin can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Atorvastatin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Atorvastatin.Approved, Vet Approved
NCX 4016The serum concentration of Atorvastatin can be increased when it is combined with NCX 4016.Investigational
NefazodoneThe metabolism of Atorvastatin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Atorvastatin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Atorvastatin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Atorvastatin can be increased when combined with Nevirapine.Approved
NiacinThe risk or severity of adverse effects can be increased when Niacin is combined with Atorvastatin.Approved, Investigational, Nutraceutical
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Atorvastatin.Approved
NicotinamideThe risk or severity of adverse effects can be increased when Nicotinamide is combined with Atorvastatin.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Atorvastatin.Approved
NilotinibThe metabolism of Atorvastatin can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Atorvastatin.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Atorvastatin.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Atorvastatin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Atorvastatin.Approved, Investigational
OlaparibThe metabolism of Atorvastatin can be decreased when combined with Olaparib.Approved
OmapatrilatThe serum concentration of Atorvastatin can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Atorvastatin can be increased when it is combined with Ombitasvir.Approved
OsimertinibThe serum concentration of Atorvastatin can be increased when it is combined with Osimertinib.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Atorvastatin.Approved, Vet Approved
PalbociclibThe serum concentration of Atorvastatin can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Atorvastatin.Approved, Investigational
ParitaprevirThe serum concentration of Atorvastatin can be increased when it is combined with Paritaprevir.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Atorvastatin.Approved
PentobarbitalThe metabolism of Atorvastatin can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Atorvastatin can be increased when it is combined with Perindopril.Approved
PhenindioneAtorvastatin may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Atorvastatin can be increased when combined with Phenobarbital.Approved
PhenprocoumonAtorvastatin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Atorvastatin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Atorvastatin can be increased when it is combined with Phosphoramidon.Experimental
PimozideThe serum concentration of Pimozide can be increased when it is combined with Atorvastatin.Approved
PioglitazoneThe metabolism of Atorvastatin can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Atorvastatin.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Atorvastatin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Atorvastatin.Approved
PosaconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Atorvastatin.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Atorvastatin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Atorvastatin.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Atorvastatin.Approved, Vet Approved
PrimidoneThe metabolism of Atorvastatin can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Atorvastatin can be increased when it is combined with Prinomastat.Investigational
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Atorvastatin.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Atorvastatin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Atorvastatin.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Atorvastatin.Approved
QuinaprilThe serum concentration of Atorvastatin can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Atorvastatin.Approved
QuinineThe serum concentration of Atorvastatin can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Atorvastatin can be decreased when combined with Rabeprazole.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
RamiprilThe serum concentration of Atorvastatin can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Atorvastatin.Approved
RanolazineThe serum concentration of Atorvastatin can be increased when it is combined with Ranolazine.Approved, Investigational
RemikirenThe serum concentration of Atorvastatin can be increased when it is combined with Remikiren.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Rescinnamine.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Atorvastatin.Approved
RifabutinThe metabolism of Atorvastatin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Atorvastatin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Atorvastatin can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Atorvastatin.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Atorvastatin.Approved, Investigational
RitonavirThe serum concentration of Atorvastatin can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Atorvastatin can be increased when it is combined with Rivaroxaban.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Atorvastatin.Approved, Investigational
RosiglitazoneThe metabolism of Atorvastatin can be decreased when combined with Rosiglitazone.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Atorvastatin.Approved, Vet Approved
SaquinavirThe serum concentration of Atorvastatin can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Atorvastatin can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Atorvastatin can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Atorvastatin.Approved
SildenafilThe metabolism of Atorvastatin can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Atorvastatin.Approved
SiltuximabThe serum concentration of Atorvastatin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Atorvastatin can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Atorvastatin can be increased when it is combined with Sitagliptin.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Atorvastatin.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Atorvastatin.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Atorvastatin.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Atorvastatin.Experimental
SpiraprilThe serum concentration of Atorvastatin can be increased when it is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Spironolactone.Approved
St. John's WortThe metabolism of Atorvastatin can be increased when combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Atorvastatin can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleThe metabolism of Atorvastatin can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Atorvastatin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Atorvastatin.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Atorvastatin.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Atorvastatin.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Atorvastatin.Approved
TelaprevirThe serum concentration of Atorvastatin can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Atorvastatin can be increased when it is combined with Telithromycin.Approved
TemocaprilThe serum concentration of Atorvastatin can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Atorvastatin.Approved
TeriflunomideThe serum concentration of Atorvastatin can be increased when it is combined with Teriflunomide.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Atorvastatin.Withdrawn
ThiorphanThe serum concentration of Atorvastatin can be increased when it is combined with Thiorphan.Experimental
TicagrelorThe serum concentration of Atorvastatin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Atorvastatin can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Atorvastatin.Approved
TipranavirThe serum concentration of Atorvastatin can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Atorvastatin can be decreased when it is combined with Tocilizumab.Approved
TolazamideAtorvastatin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideAtorvastatin may increase the hypoglycemic activities of Tolbutamide.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Atorvastatin.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Atorvastatin.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Atorvastatin.Approved, Investigational
TrabectedinAtorvastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TrandolaprilThe serum concentration of Atorvastatin can be increased when it is combined with Trandolapril.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Atorvastatin.Approved
TrimethoprimThe metabolism of Atorvastatin can be decreased when combined with Trimethoprim.Approved, Vet Approved
UbenimexThe serum concentration of Atorvastatin can be increased when it is combined with Ubenimex.Experimental
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Atorvastatin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Atorvastatin.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Atorvastatin.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Atorvastatin.Approved
VenlafaxineThe metabolism of Atorvastatin can be decreased when combined with Venlafaxine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Atorvastatin.Approved
VildagliptinThe serum concentration of Atorvastatin can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Atorvastatin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Atorvastatin.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Atorvastatin.Approved
VoriconazoleThe serum concentration of Atorvastatin can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinAtorvastatin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Atorvastatin can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Atorvastatin.Approved
ZiprasidoneThe metabolism of Atorvastatin can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid drastic changes in dietary habit.
  • Avoid taking grapefruit or grapefruit juice throughout treatment. Grapefruit can significantly increase serum levels of this product.
  • Food may decrease maximum plasma levels and area under the curve, but this is clinically inconsequential according to the manufacturer.
  • Take with low fat meal.
References
Synthesis Reference

Zlatko Pflaum, "Process for the preparation of amorphous atorvastatin." U.S. Patent US20020183527, issued December 05, 2002.

US20020183527
General References
  1. Rouleau J: Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. Am J Med. 2005 Dec;118 Suppl 12A:28-35. [PubMed:16356805 ]
  2. Maggon K: Best-selling human medicines 2002-2004. Drug Discov Today. 2005 Jun 1;10(11):739-42. [PubMed:15922927 ]
External Links
ATC CodesC10AA05 — AtorvastatinC10BX06 — Atorvastatin, acetylsalicylic acid and ramiprilC10BA05 — Atorvastatin and ezetimibeC10BX11 — Atorvastatin, amlodipine and perindoprilC10BX03 — Atorvastatin and amlodipineC10BX08 — Atorvastatin and acetylsalicylic acid
AHFS Codes
  • 24:06.08
PDB EntriesNot Available
FDA labelDownload (62 KB)
MSDSDownload (57.4 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingBasic ScienceObstructive Sleep Apnea of Adult1
0RecruitingTreatmentCancer of Breast / Cancer, Breast / Tumors, Breast1
0RecruitingTreatmentEndometrial Cancers1
0Unknown StatusPreventionStroke, Ischemic / Ventilator-Associated Pneumonia (VAP)1
1Active Not RecruitingTreatmentAcute Coronary Syndromes (ACS) / Inflammatory Reaction / Myocardial Infarction (MI) / Reperfusion Injury1
1Active Not RecruitingTreatmentHealthy Male Subjects1
1Active Not RecruitingTreatmentHealthy Volunteers1
1CompletedNot AvailableAcute Coronary Syndromes (ACS)1
1CompletedNot AvailableEffect of Atorvastatin on the Pharmacokinetics of Lomitapide1
1CompletedNot AvailableHIV Disease / Hypercholesterolaemia1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Atorvastatin1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Atorvastatin / Pharmacokinetics of Isavuconazole1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableHypercholesterolaemia3
1CompletedNot AvailableHypertension,Essential1
1CompletedNot AvailableHypertensive1
1CompletedNot AvailablePediatric Heterozygous Hypercholesterolemia1
1CompletedBasic ScienceCoronary Heart Disease (CHD)1
1CompletedBasic ScienceDiabetes / Healthy Volunteers1
1CompletedBasic ScienceDyslipidemias1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics1
1CompletedBasic ScienceHypercholesterolaemia1
1CompletedHealth Services ResearchHealthy Controls1
1CompletedOtherHealthy Volunteers1
1CompletedPreventionAtypical Ductal Breast Hyperplasia / Cancer, Breast / Ductal Breast Carcinoma In Situ / Lobular Breast Carcinoma In Situ1
1CompletedTreatmentAcute and Chronic Inflammation / Autoimmune Diseases / Disorder of Pleura and Pleural Cavity / Disorder of Synovium / Felty's Syndrome / Rheumatoid Arthritis / Rheumatoid Nodules / Sjogren's Syndrome1
1CompletedTreatmentAtherosclerotic Vascular Diseases1
1CompletedTreatmentAutoimmune Diseases / Disseminated or Multiple Sclerosis Nos / Disseminated Sclerosis / Multiple Sclerosis, Acute Relapsing / Multiple Sclerosis, Chronic Progressive / Multiple Sclerosis, Primary Progressive1
1CompletedTreatmentCholesterol, LDL / Hypercholesterolaemia1
1CompletedTreatmentDiabetes / Healthy Volunteers1
1CompletedTreatmentDiseases of the Circulatory System / Hypertension,Essential1
1CompletedTreatmentDyslipidemias1
1CompletedTreatmentEnd-Stage Kidney Disease1
1CompletedTreatmentEndometriosis / Malignant Neoplasm of Prostate1
1CompletedTreatmentEpilepsies1
1CompletedTreatmentHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
1CompletedTreatmentHealthy Participants1
1CompletedTreatmentHealthy Volunteers16
1CompletedTreatmentHealthy Volunteers / Normocholesterolaemic Men / Normozoospermic Men1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHyperlipidemias1
1CompletedTreatmentHyperlipidemias / Hypertension,Essential2
1CompletedTreatmentHyperlipidemias / Hypertensive2
1CompletedTreatmentPharmacokinetics1
1CompletedTreatmentSleep disorders and disturbances1
1Not Yet RecruitingNot AvailableHealthy Male Subjects1
1RecruitingBasic ScienceHealthy Volunteers1
1RecruitingTreatmentDyslipidemias1
1RecruitingTreatmentHealthy Volunteers1
1RecruitingTreatmentHypertension, Hyperlipidemia1
1TerminatedTreatmentDiabetes, Diabetes Mellitus Type 11
1Unknown StatusTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Dyslipidemia (Fredrickson Type Ⅱb)1
1Unknown StatusTreatmentHealthy Volunteers1
1Unknown StatusTreatmentPlasma Cell Myeloma1
1Unknown StatusTreatmentStrokes1
1WithdrawnBasic ScienceAdvanced Adenocarcinoma of the Colon or Rectum1
1, 2CompletedTreatmentMetabolic Syndromes1
1, 2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1, 2Not Yet RecruitingPreventionPrimary Arteriovenous Fistula Failure1
1, 2Not Yet RecruitingTreatmentCerebral Cavernous Malformations1
1, 2Not Yet RecruitingTreatmentEbola Virus Disease1
1, 2RecruitingTreatmentMucocutaneous Lymph Node Syndrome1
1, 2RecruitingTreatmentVenous Thromboembolism1
1, 2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hyperlipidemias1
1, 2Unknown StatusTreatmentMetabolic Syndromes1
1, 2Unknown StatusTreatmentStenosis1
2Active Not RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Active Not RecruitingPreventionProstatic Neoplasms1
2Active Not RecruitingSupportive CareAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
2Active Not RecruitingTreatmentNonalcoholic Steatohepatitis1
2Active Not RecruitingTreatmentSpastic Paraplegia, Hereditary1
2Active Not RecruitingTreatmentVitiligo1
2CompletedBasic ScienceHIV Disease1
2CompletedDiagnosticHealthy Volunteers1
2CompletedPreventionAlzheimer's Disease (AD)1
2CompletedPreventionDisseminated Sclerosis1
2CompletedPreventionHip Fractures / Inflammatory Reaction / Myocardial Ischemia1
2CompletedPreventionMalignant Neoplasm of Colon / Precancerous Conditions / Rectal Carcinoma1
2CompletedPreventionMetabolic Syndromes1
2CompletedSupportive CareNeoplasms, Malignant1
2CompletedTreatmentALL, Childhood / Cardiovascular Disease (CVD) / Childhood NHL1
2CompletedTreatmentAcute Coronary Syndromes (ACS)1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD) / Smoking1
2CompletedTreatmentCancer, Breast / One to five years postmenopausal1
2CompletedTreatmentCardiovascular Disease (CVD)1
2CompletedTreatmentCardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Renal Dysfunction1
2CompletedTreatmentCardiovascular Disease (CVD) / Renal Dysfunction2
2CompletedTreatmentCarotid Atherosclerosis1
2CompletedTreatmentChronic Hepatitis C Infection1
2CompletedTreatmentChronic Subdural Hematomas1
2CompletedTreatmentCrohns Disease1
2CompletedTreatmentDiabetes Mellitus (DM)1
2CompletedTreatmentDiabetes Mellitus (DM) / Hypercholesterolaemia / Metabolic Syndromes1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentDiabetes / Ulcus Cruris1
2CompletedTreatmentDisseminated Sclerosis1
2CompletedTreatmentDyslipidemias8
2CompletedTreatmentGlomerulosclerosis, Focal Segmental1
2CompletedTreatmentHIV-1 Infections1
2CompletedTreatmentHigh Cholesterol1
2CompletedTreatmentHypercholesterolaemia10
2CompletedTreatmentHypercholesterolaemia / Hyperlipidemias / Muscle Soreness1
2CompletedTreatmentHyperlipidemias5
2CompletedTreatmentMalignant Neoplasm of Prostate1
2CompletedTreatmentOsteoarthritis of the Knees1
2CompletedTreatmentPlatelets Dysfunction1
2CompletedTreatmentPolycystic Ovaries Syndrome1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentPulmonary Hypertension (PH)1
2CompletedTreatmentRenal Cancers / Renal Cell Adenocarcinoma1
2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentSarcoidosis, Pulmonary1
2CompletedTreatmentVascular Diseases1
2Enrolling by InvitationTreatmentAngioplasty, Transluminal, Percutaneous Coronary / Myocardial Infarction (MI) / Transplantation, Stem Cell1
2Enrolling by InvitationTreatmentSickle Cell Disorders / Sickle Cell Nephropathy1
2Not Yet RecruitingPreventionCancers / Cardiotoxicity / Heart Failure, Unspecified1
2Not Yet RecruitingTreatmentAngioplasty, Transluminal, Percutaneous Coronary / Myocardial Infarction (MI) / Transplantation, Stem Cell1
2Not Yet RecruitingTreatmentBipolar Disorder (BD)1
2Not Yet RecruitingTreatmentChronic Subdural Hematomas1
2Not Yet RecruitingTreatmentDyslipidemias1
2Not Yet RecruitingTreatmentNeoplasms, Breast1
2RecruitingPreventionAdult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Aggressive Non-Hodgkin Lymphoma / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Diffuse Large B -Cell Lymphoma / DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Aggressive Adult Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Stage I Adult Hodgkin Lymphoma / Stage I Aggressive Adult Non-Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Diffuse Large B-Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Contiguous Adult Aggressive Non-Hodgkin Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Non-Contiguous Aggressive Adult Non-Hodgkin Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Aggressive Adult Non-Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Diffuse Large B-Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Aggressive Adult Non-Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Small Lymphocytic Lymphoma / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingPreventionCancer, Breast1
2RecruitingPreventionCoronary Artery Disease1
2RecruitingPreventionHyperlipidemias / Hypertensive1
2RecruitingPreventionNasopharyngeal Carcinoma / Radiation Therapy Complication1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentCancer, Breast / Cardiotoxicity / Heart Diseases / Myocardial Dysfunction1
2RecruitingTreatmentFlu caused by Influenza1
2RecruitingTreatmentGlioblastoma Multiforme1
2RecruitingTreatmentHeart Failure, Unspecified1
2RecruitingTreatmentHypercholesterolaemia1
2RecruitingTreatmentHypertensive1
2RecruitingTreatmentMalignant Neoplasm of Prostate1
2RecruitingTreatmentNon-Alcoholic Steatohepatitis1
2RecruitingTreatmentScleroderma1
2TerminatedBasic ScienceCoronary Artery Disease / Dyslipidemias1
2TerminatedPreventionAvascular Necrosis1
2TerminatedTreatmentAsthma Bronchial1
2TerminatedTreatmentHypercholesterolaemia / Venous Thromboembolism1
2TerminatedTreatmentMild Traumatic Brain Injury (MTBI) / Post-Traumatic Stress Disorder (PTSD) / Traumatic Brain Injury (TBI)1
2TerminatedTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
2Unknown StatusPreventionAcute Non-ST-segment Elevation Myocardial Infarction / Stable Angina (SA) / Unstable Angina (UA)1
2Unknown StatusPreventionCancer, Breast1
2Unknown StatusPreventionGraft Versus Host Disease (GVHD)1
2Unknown StatusPreventionProstatic Neoplasms1
2Unknown StatusTreatmentAneurysm, Coronary / Mucocutaneous Lymph Node Syndrome1
2Unknown StatusTreatmentLeukemias / Non-Hodgkin's Lymphoma (NHL)1
2, 3CompletedPreventionMyocardial Infarction (MI) / Renal Failure / Strokes1
2, 3CompletedPreventionProphylaxis of Contrast-induced nephropathy1
2, 3CompletedTreatmentAcute Kidney Dysfunction1
2, 3CompletedTreatmentArterial Occlusive Diseases / Insulin Resistance / Intermittent Claudication1
2, 3CompletedTreatmentAsthma Bronchial1
2, 3CompletedTreatmentChronic Periodontitis4
2, 3CompletedTreatmentDyslipidemias1
2, 3RecruitingPreventionCognitively Normal Older Adults / Family History of Alzheimer's Disease / Hypertensive / Subjective Cognitive Decline1
2, 3RecruitingTreatmentHyperlipidemias1
2, 3TerminatedTreatmentAdvanced Cancers1
2, 3Unknown StatusTreatmentSystemic Lupus Erythematosus (SLE)1
2, 3WithdrawnTreatmentHIV-infection/AIDS / Immune Reconstitution Inflammatory Syndrome / Immune Reconstitution Syndrome / Tuberculosis1
3Active Not RecruitingPreventionDiabetes, Diabetes Mellitus Type 11
3Active Not RecruitingTreatmentCoronary Artery Disease1
3Active Not RecruitingTreatmentHypercholesterolaemia2
3Active Not RecruitingTreatmentImpaired Renal Function1
3CompletedPreventionAcute Coronary Syndromes (ACS)1
3CompletedPreventionAortic Aneurism / Myocardial Infarction (MI) / Peripheral Vascular Disease (PVD)1
3CompletedPreventionCoronary Artery Disease1
3CompletedPreventionHeart Valve Diseases1
3CompletedPreventionProphylaxis of preeclampsia1
3CompletedTreatmentAcute Coronary Syndromes (ACS)2
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAssess the Periprocedural Myocardial Necrosis1
3CompletedTreatmentAtherosclerosis3
3CompletedTreatmentAtherosclerosis / Calcifications, Vascular / Dyslipidemias / Inflammatory Reaction1
3CompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD)1
3CompletedTreatmentAtherosclerosis / Coronary Artery Disease / Hypercholesterolaemia1
3CompletedTreatmentAtherosclerotic Disease / Coronary Heart Disease (CHD) / Hypercholesterolaemia1
3CompletedTreatmentBMI >30 kg/m2 / Dyslipidemias1
3CompletedTreatmentBMI >30 kg/m2 / Dyslipidemias / Insulin Resistance1
3CompletedTreatmentCardiovascular Disorder / Diabetes Mellitus (DM)1
3CompletedTreatmentChronic Kidney Disease (CKD)1
3CompletedTreatmentCombined (Atherogenic) Dyslipidemia / Coronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia1
3CompletedTreatmentCoronary Arteriosclerosis / Coronary Heart Disease (CHD) / Hyperlipidemias1
3CompletedTreatmentCoronary Artery Atherosclerosis1
3CompletedTreatmentCoronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia2
3CompletedTreatmentCoronary Heart Disease (CHD) / Hypercholesterolaemia1
3CompletedTreatmentDiabetes Mellitus, Insulin-Dependent / Hypercholesterolaemia1
3CompletedTreatmentDyslipidemias1
3CompletedTreatmentDyslipidemias / Hypercholesterolaemia3
3CompletedTreatmentDyslipidemias / Hypercholesterolaemia / Hyperlipidemias1
3CompletedTreatmentDyslipidemias / Hypercholesterolemia, Familial1
3CompletedTreatmentDyslipidemias / Hypertensive1
3CompletedTreatmentDyslipidemias / Type 2 Diabetes Mellitus2
3CompletedTreatmentHeterozygous Familial Hypercholesterolemia1
3CompletedTreatmentHypercholesterolaemia26
3CompletedTreatmentHypercholesterolaemia / Metabolic Syndromes1
3CompletedTreatmentHypercholesterolaemia / Primary Biliary Cirrhosis (PBC)1
3CompletedTreatmentHypercholesterolaemia / Type 2 Diabetes Mellitus1
3CompletedTreatmentHypercholesterolemia, Familial2
3CompletedTreatmentHypercholesterolemia, Familial / Hyperlipidemias2
3CompletedTreatmentHypercholesterolemia, Familial / Mixed hypercholesterolemia1
3CompletedTreatmentHyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events1
3CompletedTreatmentHyperlipidemias9
3CompletedTreatmentHyperlipidemias / Hypertension,Essential1
3CompletedTreatmentHyperlipidemias / Mixed hypercholesterolemia1
3CompletedTreatmentHyperlipoproteinemia Type iv / Hypertriglyceridemias1
3CompletedTreatmentHypertriglyceridemias1
3CompletedTreatmentHypertrophic Cardiomyopathy1
3CompletedTreatmentImpaired Renal Function1
3CompletedTreatmentLupus Erythematosus, Systemic1
3CompletedTreatmentMetabolic Syndromes1
3CompletedTreatmentPrimary Hyperlipidemia and Mixed Dyslipidemia1
3CompletedTreatmentType 2 Diabetes Mellitus2
3CompletedTreatmentMixed hypercholesterolemia2
3Not Yet RecruitingPreventionMyocardial Oedema1
3Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3RecruitingPreventionAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
3RecruitingPreventionCardiovascular Disease (CVD) / Coronary Artery Disease / Type 2 Diabetes Mellitus1
3RecruitingPreventionCarotid Artery Stenosis / Strokes1
3RecruitingTreatmentAortic Valve Stenosis / Ventricular Hypertrophy1
3RecruitingTreatmentAtherosclerosis / Dyslipidemias1
3RecruitingTreatmentBicuspid Aortic Valve (BAV)1
3RecruitingTreatmentCancers / Overall Survival / Quality of Life1
3RecruitingTreatmentCombined Dyslipidemia1
3RecruitingTreatmentDiabetes, Hyperlipidemia, Mixed Dyslipidemia1
3RecruitingTreatmentDyslipidemias / Type 2 Diabetes Mellitus1
3RecruitingTreatmentHypercholesterolaemia1
3TerminatedPreventionInflammatory Reaction / Nonvalvular Atrial Fibrillation1
3TerminatedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
3TerminatedTreatmentCardiovascular Disease (CVD)1
3TerminatedTreatmentCoronary Artery Disease / High Cholesterol1
3TerminatedTreatmentCoronary Heart Disease (CHD) / Diabetes Mellitus (DM)1
3TerminatedTreatmentDyslipidemias / Hypercholesterolaemia / Hyperlipidemias1
3TerminatedTreatmentDyslipidemias / Hyperlipidemias1
3TerminatedTreatmentHypercholesterolaemia5
3TerminatedTreatmentHyperlipidemias1
3TerminatedTreatmentHyperlipoproteinemia Type III1
3TerminatedTreatmentStable Coronary Artery Disease Undergoing PCI1
3TerminatedTreatmentType 2 Diabetes Mellitus1
3TerminatedTreatmentMixed hypercholesterolemia1
3Unknown StatusPreventionContrast Induced Nephropathy (CIN)1
3Unknown StatusTreatmentAbdominal Surgeries1
3Unknown StatusTreatmentBranch Retinal Vein Occlusion / Central Retinal Vein Occlusion (CRVO) / Retinal Vein Occlusions(RVO) / Retinal Vein Thrombosis / Thrombosis1
3Unknown StatusTreatmentCoronary Angioplasty / Coronary Artery Disease1
3Unknown StatusTreatmentHyperlipidemia, Familial Combined1
3Unknown StatusTreatmentHyperlipidemias1
3Unknown StatusTreatmentST Elevation Myocardial Infarction (STEMI)1
3Unknown StatusTreatmentStable Coronary Artery Disease1
3Unknown StatusTreatmentMixed hypercholesterolemia1
3WithdrawnTreatmentHypertriglyceridemias1
3WithdrawnTreatmentPsoriasis1
4Active Not RecruitingNot AvailableAtherosclerosis / Carotid Artery Diseases / Coronary Artery Disease1
4Active Not RecruitingTreatmentAging-related Inflammation in HIV-infected Patients1
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD)1
4Active Not RecruitingTreatmentHIV Dementia2
4Active Not RecruitingTreatmentHypercholesterolaemia / Type 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentStroke, Ischemic1
4CompletedNot AvailableAbdominal Aortic Aneurysms (AAA)1
4CompletedNot AvailableCardiovascular Disease (CVD) / Cholesterol, LDL / Cognition / Type 2 Diabetes Mellitus1
4CompletedNot AvailableDyslipidemias / Vascular Diseases1
4CompletedNot AvailableHealthy Volunteers3
4CompletedNot AvailableHypercholesterolaemia4
4CompletedNot AvailablePrediabetic State1
4CompletedBasic ScienceAtherosclerosis / Coronary Artery Disease / Endothelial Dysfunction / HMG-CoA Reductase Inhibitor Toxicity / Oxidative Stress1
4CompletedBasic ScienceBone destruction / Hypercholesterolaemia1
4CompletedBasic ScienceHyperlipidemias / Metabolic Syndromes / Renal Failure Chronic Requiring Hemodialysis / Type 2 Diabetes Mellitus1
4CompletedBasic SciencePeripheral Arterial Disease (PAD)1
4CompletedDiagnosticMuscular Diseases1
4CompletedDiagnosticMyopathies1
4CompletedDiagnosticMyotoxicity of Atorvastatin Treatment1
4CompletedPreventionAcute Coronary Syndromes (ACS)2
4CompletedPreventionAcute Kidney Injury (AKI) / Aortic Surgery1
4CompletedPreventionAging / Alzheimer's Disease (AD)1
4CompletedPreventionCardiac Insufficiency Following Cardiac Surgery / Disorder; Heart, Functional, Postoperative, Cardiac Surgery / Ischaemia-reperfusion Injury / Nonvalvular Atrial Fibrillation1
4CompletedPreventionCardiovascular Disease (CVD) / Cerebrovascular Accidents / Coronary Heart Disease (CHD)1
4CompletedPreventionCerebrovascular Accidents / Coronary Artery Bypass Graft / Major Coronary Event / Revascularization / Unstable Angina (UA)1
4CompletedPreventionContrast Induced Nephropathy (CIN)1
4CompletedPreventionCoronary Artery Bypass Grafting (CABG) Surgery1
4CompletedPreventionEndothelial Dysfunction / Ischemia Reperfusion Injury1
4CompletedPreventionHemostasis / Inflammatory Reaction / Magnetic Resonance Imaging (MRI) / Neuropsychology / Nonvalvular Atrial Fibrillation1
4CompletedPreventionMyocardial Infarction (MI)1
4CompletedPreventionSystemic Lupus Erythematosus (SLE)1
4CompletedPreventionType 2 Diabetes Mellitus1
4CompletedScreeningInflammatory Reaction1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Dyslipidemias1
4CompletedTreatmentAcute Myocardial Infarction (AMI)2
4CompletedTreatmentAngina Pectoris / Hypercholesterolaemia / Hypertensive1
4CompletedTreatmentAnginal Pain1
4CompletedTreatmentAngioplasty / Myocardial Infarction (MI) / Percutaneous Coronary1
4CompletedTreatmentArrythmias1
4CompletedTreatmentArrythmias / Endothelial Dysfunction / Inflammatory Reaction / Nonvalvular Atrial Fibrillation1
4CompletedTreatmentArteriosclerosis / Calcinosis / Hyperparathyroidism, Secondary1
4CompletedTreatmentAtherosclerosis1
4CompletedTreatmentAtherosclerosis / Coronary Artery Disease1
4CompletedTreatmentAtherosclerosis / Coronary Heart Disease (CHD) / Diabetes / Dyslipidemias / Strokes1
4CompletedTreatmentAtherosclerosis / Hypercholesterolaemia1
4CompletedTreatmentBMI >30 kg/m2 / Cardiovascular Disease (CVD) / Hypertriglyceridemias / Lipid Disorders1
4CompletedTreatmentBronchiectasis2
4CompletedTreatmentCVD1
4CompletedTreatmentCardiovascular Disease (CVD)2
4CompletedTreatmentCardiovascular Disease (CVD) / Dyslipidemias / Hypercholesterolaemia1
4CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Myocardial Diseases / Myocardial Ischemia / Prophylaxis of cardiomyopathy1
4CompletedTreatmentCardiovascular Disease (CVD) / Ischemia Reperfusion Injury1
4CompletedTreatmentCerebrovascular Accidents / Coronary Arteriosclerosis / Dyslipidemias / Peripheral Vascular Disease (PVD) / Type 2 Diabetes Mellitus2
4CompletedTreatmentCerebrovascular Accidents / Hypercholesterolaemia1
4CompletedTreatmentChronic Hepatitis C Infection1
4CompletedTreatmentChronic Kidney Disease (CKD)1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentChronic Periaortitis / Intrabony Periodontal Defect1
4CompletedTreatmentCongestive Heart Failure (CHF)1
4CompletedTreatmentCoronary Arteriosclerosis1
4CompletedTreatmentCoronary Arteriosclerosis / Hypercholesterolaemia2
4CompletedTreatmentCoronary Artery Bypass Surgery / Elective Surgical Procedure1
4CompletedTreatmentCoronary Artery Disease1
4CompletedTreatmentCoronary Artery Disease / Hypercholesterolaemia3
4CompletedTreatmentCoronary Artery Disease / Hyperlipidemias1
4CompletedTreatmentCoronary Heart Disease (CHD) / Hypercholesterolaemia2
4CompletedTreatmentDiabetes Mellitus (DM)1
4CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Dyslipidemias1
4CompletedTreatmentDyslipidemias7
4CompletedTreatmentDyslipidemias / Hypertensive3
4CompletedTreatmentHealthy Volunteers2
4CompletedTreatmentHeart Failure, Unspecified1
4CompletedTreatmentHypercholesterolaemia10
4CompletedTreatmentHypercholesterolaemia / Hypertensive1
4CompletedTreatmentHypercholesterolemia With Type2DM1
4CompletedTreatmentHypercholesterolemia, Familial1
4CompletedTreatmentHyperlipidemias1
4CompletedTreatmentHyperlipidemias / Hypertensive1
4CompletedTreatmentHypertensive / Stable Chronic Kidney Disease1
4CompletedTreatmentHypertriglycemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentMetabolic Syndromes1
4CompletedTreatmentMulti-vessel Diseases, Angina1
4CompletedTreatmentMyocardial Infarction (MI) / Reperfusion Injury1
4CompletedTreatmentChronic, stable Angina pectoris / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / Unstable Angina Pectoris1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentStable Angina (SA)1
4CompletedTreatmentStroke, Ischemic1
4CompletedTreatmentType 2 Diabetes Mellitus1
4CompletedTreatmentType IIa and IIb Hypercholesterolaemia1
4CompletedTreatmentVascular Surgery1
4CompletedTreatmentTransient ischemia attacks1
4Enrolling by InvitationBasic ScienceDrug intolerance1
4Enrolling by InvitationPreventionDisability Free Survival / Elderly / Healthy Volunteers / Independent Living1
4Enrolling by InvitationTreatmentCerebral Infarctions / CLOPIDOGREL, POOR METABOLISM of (Disorder)1
4Enrolling by InvitationTreatmentComplete Occlusion of Coronary Artery / Hibernation, Myocardial1
4Not Yet RecruitingNot AvailableCardiovascular Disease (CVD)1
4Not Yet RecruitingDiagnosticCoronary Artery Disease1
4Not Yet RecruitingPreventionCardiovascular Disease (CVD)1
4Not Yet RecruitingTreatmentArterial Hypertension / Blood Pressures / Dyslipidemias / Lipid Metabolism Disorders1
4Not Yet RecruitingTreatmentCarotid Artery Stenosis1
4Not Yet RecruitingTreatmentCoronary Artery Disease2
4RecruitingDiagnosticHyperlipidemias1
4RecruitingPreventionAcute Coronary Syndromes (ACS)1
4RecruitingPreventionAdverse Effects / Cardiovascular Disease (CVD) / Hyperlipidemias1
4RecruitingPreventionCardiothoracic Surgery / Post-Operative Atrial Fibrillation1
4RecruitingPreventionCoronary Artery Disease1
4RecruitingPreventionHepatocellular,Carcinoma1
4RecruitingPreventionHypertensive / Strokes / Transient Ischaemic Attack (TIA)1
4RecruitingTreatmentAcute Coronary Syndromes (ACS)1
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / Hypercholesterolaemia1
4RecruitingTreatmentCardiovascular Disease (CVD)1
4RecruitingTreatmentCoronary Artery Disease1
4RecruitingTreatmentDental Plaque1
4RecruitingTreatmentDiabetes Mellitus (DM) / Dyslipidemias / Fatty Liver1
4RecruitingTreatmentDiabetes Mellitus Type 2 Platelets Reactivity Statin1
4RecruitingTreatmentHeart Failure, Unspecified1
4RecruitingTreatmentMyocardial Infarction (MI)1
4RecruitingTreatmentSevere Hypercholesterolemia1
4RecruitingTreatmentType 2 Diabetes Mellitus1
4TerminatedNot AvailableHypertension and Cardiovascular Risk Factors1
4TerminatedNot AvailableStatin Adverse Reaction / Statin-Associated Myopathy1
4TerminatedDiagnosticMyopathic Conditions1
4TerminatedPreventionAtherosclerosis / Carotid Artery Stenosis / Strokes1
4TerminatedPreventionCardiovascular Disease (CVD) / Synovitis of osteoarthritis1
4TerminatedPreventionCoarctation of the Aorta1
4TerminatedPreventionHypertensive1
4TerminatedTreatmentAtherosclerosis / Coronary Artery Disease / Hypercholesterolaemia1
4TerminatedTreatmentChronic Kidney Disease (CKD) / High Cholesterol1
4TerminatedTreatmentHypercholesterolaemia1
4TerminatedTreatmentHyperlipidemias / Non-Insulin Dependent Diabetes Mellitus / Type 2 Diabetes Mellitus1
4TerminatedTreatmentStable Angina (SA)1
4Unknown StatusNot AvailableCoronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Non-Coronary Atherosclerotic Disease1
4Unknown StatusNot AvailableDyslipidemia in Patients With Diabetes Mellitus1
4Unknown StatusPreventionCarotid Stenosis1
4Unknown StatusPreventionCholesterol, HDL1
4Unknown StatusPreventionCoronary Heart Disease (CHD)1
4Unknown StatusPreventionEndothelium / Hydroxymethylglutaryl-CoA Reductase Inhibitors1
4Unknown StatusPreventionGeneral Surgery / Prevention / Thrombosis1
4Unknown StatusPreventionVaccination Failure / Viral Hepatitis B1
4Unknown StatusTreatmentAcute Anterior Myocardial Infarction1
4Unknown StatusTreatmentAcute Coronary Syndromes (ACS)1
4Unknown StatusTreatmentAngina Pectoris, Variant1
4Unknown StatusTreatmentAngina, Prinzmetal's1
4Unknown StatusTreatmentAortic Valve Stenosis1
4Unknown StatusTreatmentArterial and Arteriolar Disorders1
4Unknown StatusTreatmentAtherosclerosis1
4Unknown StatusTreatmentAtherosclerosis / Inflammatory Reaction1
4Unknown StatusTreatmentCoronary Artery Disease3
4Unknown StatusTreatmentDiabetes Mellitus (DM) / Hypertensive1
4Unknown StatusTreatmentDiabetes Mellitus, Hypercholessterolemia1
4Unknown StatusTreatmentDrug-eluting Stent (DES)1
4Unknown StatusTreatmentFocus of Study1
4Unknown StatusTreatmentHypertensive1
4Unknown StatusTreatmentMyocardial Infarction (MI) / Unstable Angina (UA)1
4Unknown StatusTreatmentST Elevation Myocardial Infarction (STEMI)1
4Unknown StatusTreatmentType 2 Diabetes Mellitus Without Insulin Treatment1
4WithdrawnTreatmentAngina Pectoris, Variant / Statins, HMG-CoA1
4WithdrawnTreatmentAtherosclerosis1
Not AvailableActive Not RecruitingPreventionAcute Kidney Injury (AKI) / Acute Renal Failure (ARF) / Delirium / ICU Delirium / Post-Operative Delirium1
Not AvailableActive Not RecruitingTreatmentRheumatoid Arthritis1
Not AvailableCompletedNot AvailableAngina Pectoris / Hypercholesterolaemia / Hypercholesterolemia, Familial / Hypertensive1
Not AvailableCompletedNot AvailableAtheroma / Atherosclerosis / Atherosclerotic Carotid Disease1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Coronary Artery Disease1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableCarotid Atherosclerosis / Metabolic Syndromes / Strokes / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableCongestive Cardiomyopathy1
Not AvailableCompletedNot AvailableEndothelial Function / Infection NOS / Inflammatory Reaction1
Not AvailableCompletedNot AvailableGynecologic Oncological Pelvic/Abdominal Surgery1
Not AvailableCompletedNot AvailableHydroxymethylglutaryl-CoA Reductase Inhibitors / Muscular Diseases1
Not AvailableCompletedNot AvailableHypercholesterolaemia3
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableCompletedBasic ScienceDifference of 12-hour AUC1
Not AvailableCompletedBasic ScienceHydroxymethylglutaryl-CoA Reductase Inhibitors / Type 2 Diabetes Mellitus1
Not AvailableCompletedDiagnosticCoronary Artery Disease / Hypercholesterolaemia / Monocyte Function1
Not AvailableCompletedPreventionAcute Kidney Injury (AKI)1
Not AvailableCompletedPreventionArrythmias1
Not AvailableCompletedPreventionCoronary Artery Bypass Graft1
Not AvailableCompletedPreventionBone destruction1
Not AvailableCompletedTreatmentAngioplasty, Transluminal, Percutaneous Coronary1
Not AvailableCompletedTreatmentAtherosclerosis1
Not AvailableCompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD) / HIV Disease / Human Immunodeficiency Virus (HIV) Infections / Inflammatory Reaction / Statins, HMG-CoA1
Not AvailableCompletedTreatmentCardiovascular Disease (CVD)1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD)1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD) / Proteinuria1
Not AvailableCompletedTreatmentCoronary Arteriosclerosis / Genetic Diseases, Inborn / Hypoalphalipoproteinemias1
Not AvailableCompletedTreatmentCoronary Artery Disease1
Not AvailableCompletedTreatmentDiastolic Heart Failure1
Not AvailableCompletedTreatmentEnd-Stage Renal Disease (ESRD)1
Not AvailableCompletedTreatmentGlomerulonephritis minimal lesion / Hyperlipidemias1
Not AvailableCompletedTreatmentHealthy Volunteers2
Not AvailableCompletedTreatmentHypercholesterolaemia / Hypertensive1
Not AvailableCompletedTreatmentHypercholesterolemia With Concomitant Type 2 Diabetes1
Not AvailableCompletedTreatmentHyperlipidemias1
Not AvailableCompletedTreatmentPolycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentShock, Septic1
Not AvailableCompletedTreatmentThoracic Surgery1
Not AvailableRecruitingBasic ScienceHyperlipidemias1
Not AvailableRecruitingTreatmentGlomerulonephritis minimal lesion1
Not AvailableRecruitingTreatmentSleep Deprivation1
Not AvailableTerminatedBasic ScienceDiabetes Mellitus (DM) / Metabolic Syndromes1
Not AvailableTerminatedPreventionRenal Dysfunction1
Not AvailableTerminatedTreatmentCoronary Artery Disease1
Not AvailableTerminatedTreatmentDiastolic Heart Failure1
Not AvailableUnknown StatusNot AvailableDisseminated Sclerosis1
Not AvailableUnknown StatusBasic ScienceAutonomic Changes of Cardiomyocytes Repolarisation / Heterogeneity of Cardiomyocytes Repolarisation1
Not AvailableUnknown StatusDiagnosticDiabetes1
Not AvailableUnknown StatusDiagnosticPeripheral Arterial Disease (PAD)1
Not AvailableUnknown StatusPreventionAtherosclerosis1
Not AvailableUnknown StatusPreventionCoronary Heart Disease (CHD)1
Not AvailableUnknown StatusPreventionInflammatory Reaction / Myocardial Infarction (MI) / Myocardial Ischemia1
Not AvailableUnknown StatusTreatmentAcute Coronary Syndromes (ACS)2
Not AvailableUnknown StatusTreatmentBlood Pressure Variability / Intracranial Artery Stenosis1
Not AvailableUnknown StatusTreatmentCongestive Heart Failure (CHF)1
Not AvailableUnknown StatusTreatmentCoronary Artery1
Not AvailableUnknown StatusTreatmentEndometriosis / Pain1
Not AvailableUnknown StatusTreatmentHypercholesterolaemia / Thrombosis1
Not AvailableUnknown StatusTreatmentNonalcoholic Fatty Liver Disease (NAFLD)1
Not AvailableUnknown StatusTreatmentMixed hypercholesterolemia1
Not AvailableWithdrawnBasic ScienceNeurocognitive Dysfunction1
Not AvailableWithdrawnTreatmentAtherosclerosis / Type 2 Diabetes Mellitus1
Not AvailableWithdrawnTreatmentComplication of Renal Dialysis1
Not AvailableWithdrawnTreatmentEndothelial Dysfunction1
Not AvailableWithdrawnTreatmentNon Alcoholic Fatty Liver Diseases (NAFLD)1
Not AvailableWithdrawnTreatmentRecurrent Prostate Cancer / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral10 mg/301
Tablet, film coatedOral20 mg/301
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral80 mg/1
Tablet, film coatedOral80 mg/301
TabletOral
TabletOral10 mg
TabletOral20 mg
TabletOral40 mg
TabletOral80 mg
Prices
Unit descriptionCostUnit
Lipitor 20 mg tablet5.0USD tablet
Lipitor 40 mg tablet5.0USD tablet
Lipitor 80 mg tablet5.0USD tablet
Lipitor 10 mg tablet3.5USD tablet
Lipitor 40 mg Tablet2.52USD tablet
Lipitor 80 mg Tablet2.52USD tablet
Lipitor 20 mg Tablet2.34USD tablet
Lipitor 10 mg Tablet1.87USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2220018 No2001-04-172016-07-08Canada
CA2521776 No2006-04-252022-05-21Canada
US4681893 No1992-09-242009-09-24Us
US5969156 Yes1997-01-082017-01-08Us
US6455574 No1998-08-112018-08-11Us
USRE42461 Yes1997-04-252017-04-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)159.2-160.7 °CNot Available
water solubilitySodium salt soluble in water, 20.4 ug/mL (pH 2.1), 1.23 mg/mL (pH 6.0)Not Available
logP5.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00063 mg/mLALOGPS
logP4.24ALOGPS
logP5.39ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)4.33ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area111.79 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity158.2 m3·mol-1ChemAxon
Polarizability59.39 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8947
Blood Brain Barrier-0.7825
Caco-2 permeable-0.8956
P-glycoprotein substrateSubstrate0.5246
P-glycoprotein inhibitor IInhibitor0.7164
P-glycoprotein inhibitor IIInhibitor0.8724
Renal organic cation transporterNon-inhibitor0.8131
CYP450 2C9 substrateNon-substrate0.7887
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6841
CYP450 1A2 substrateNon-inhibitor0.8551
CYP450 2C9 inhibitorNon-inhibitor0.719
CYP450 2D6 inhibitorNon-inhibitor0.9042
CYP450 2C19 inhibitorNon-inhibitor0.6191
CYP450 3A4 inhibitorNon-inhibitor0.6675
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6894
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7777
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.5686 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9904
hERG inhibition (predictor II)Non-inhibitor0.5101
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Nadph binding
Specific Function:
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including ubiquinone and geranylgeranyl proteins.
Gene Name:
HMGCR
Uniprot ID:
P04035
Molecular Weight:
97475.155 Da
References
  1. Davidson MH: Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002 Mar;11(3):125-41. [PubMed:12769127 ]
  2. Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M: Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther. 2003 Jun;8(2):123-6. [PubMed:12808485 ]
  3. Baxter JD, Webb P, Grover G, Scanlan TS: Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab. 2004 May-Jun;15(4):154-7. [PubMed:15109613 ]
  4. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y: Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun. 2004 Nov 12;324(2):835-9. [PubMed:15474503 ]
  5. Bosel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, Megow D, Dirnagl U, Hortnagl H, Fink KB, Endres M: Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem. 2005 Mar;92(6):1386-98. [PubMed:15748157 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Virus receptor activity
Specific Function:
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also ...
Gene Name:
DPP4
Uniprot ID:
P27487
Molecular Weight:
88277.935 Da
References
  1. Taldone T, Zito SW, Talele TT: Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Bioorg Med Chem Lett. 2008 Jan 15;18(2):479-84. Epub 2007 Dec 3. [PubMed:18068977 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Transcription regulatory region dna binding
Specific Function:
Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes (such as the CYP1A1 gene). Mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. Involved in cell-cycle regulation. Likely to play an important role in the development and matu...
Gene Name:
AHR
Uniprot ID:
P35869
Molecular Weight:
96146.705 Da
References
  1. Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR: Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol. 2007 Jun;71(6):1475-86. Epub 2007 Feb 27. [PubMed:17327465 ]
  2. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM: Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013 Oct;52(10):815-31. doi: 10.1007/s40262-013-0075-4. [PubMed:23703578 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. [PubMed:17178259 ]
  2. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 Nov;28(11):1369-78. [PubMed:11038166 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 Nov;28(11):1369-78. [PubMed:11038166 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 Nov;28(11):1369-78. [PubMed:11038166 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Stormo C, Bogsrud MP, Hermann M, Asberg A, Piehler AP, Retterstol K, Kringen MK: UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7. doi: 10.1007/s40291-013-0031-x. [PubMed:23580084 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Stormo C, Bogsrud MP, Hermann M, Asberg A, Piehler AP, Retterstol K, Kringen MK: UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7. doi: 10.1007/s40291-013-0031-x. [PubMed:23580084 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang E, Casciano CN, Clement RP, Johnson WW: HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001 Jun;18(6):800-6. [PubMed:11474784 ]
  2. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35. doi: 10.1002/ijc.24885. [PubMed:19739078 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278 ]
  2. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25. [PubMed:19940267 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name:
ABCC5
Uniprot ID:
O15440
Molecular Weight:
160658.8 Da
References
  1. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25. [PubMed:19940267 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25. [PubMed:19940267 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, Bohm M, Felix SB, Vogelgesang S, Jedlitschky G, Siegmund W, Warzok R, Kroemer HK: Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006 Dec;80(6):607-20. [PubMed:17178262 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Klatt S, Fromm MF, Konig J: The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):244-50. doi: 10.1111/bcpt.12031. Epub 2012 Dec 6. [PubMed:23121773 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Becker ML, Elens LL, Visser LE, Hofman A, Uitterlinden AG, van Schaik RH, Stricker BH: Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Pharmacogenomics J. 2013 Jun;13(3):251-6. doi: 10.1038/tpj.2011.59. Epub 2011 Dec 20. [PubMed:22186618 ]
Drug created on June 13, 2005 07:24 / Updated on June 27, 2017 20:05